研究者情報

キクチ　エイジ   KIKUCHI EIJI   菊地栄次    所属   医学部医学科 腎泌尿器外科学    職種   主任教授
言語種別	日本語
発表タイトル	Avelumab maintenance after first-line (1L) dose-dense (dd)MVAC in patients (pts) with advanced urothelial carcinoma (aUC) in Japan: JAVEMACS chart review study
会議名	第112回日本泌尿器科学会総会
学会区分	全国規模の学会
発表形式	口頭
講演区分	一般
発表者・共同発表者	Ikeda Masaomi, Fujimoto Kiyohide, Miura Noriyoshi, Taoka Rikiya, Nishihara Kiyoaki, Ikarashi Daiki, Naito Sei, Shimizu Fumitaka, Fujihara Atsuko, Kambe Anzu, Shono Michihiro, Nakagawa Tohru, Kikuchi Eiji
発表年月日	2025/04/18
開催地 （都市, 国名）	福岡県福岡市
開催期間	2025/04/17～2025/04/19
概要	[Object] Avelumab maintenance treatment (tx) is approved in Japan for patients (pts) with curatively unresectable UC not progressed after platinum-based chemotherapy (PBC). We report data from the JAVEMACS chart review study of avelumab maintenance in Japan in pts who received 1L ddMVAC. [Methods] In this retrospective study, medical charts of pts with aUC who started avelumab maintenance tx after 1L PBC between Feb 2021 and Dec 2023 were reviewed. [Results] Of 354 pts at 26 sites, 33 pts at 11 sites received 1L ddMVAC. In this subgroup, median age was 72 y (range, 49-82); 72.7% were male; ECOG performance status was 0/1/≧2 in 69.7%/24.2%/6.1%; primary tumor location was bladder in 45.5% and renal pelvis or ureter in 48.5%; and 54.5% had creatinine clearance ≧ 60 mL/min. No. of 1L PBC cycles was 1-3/4/5-6 in 12.1%/69.7%/18.2%. Response to ddMVAC was complete response/partial response/stable disease in 9.1%/63.6%/27.3%. Median duration from PBC start to avelumab start was 13.1 wks (range, 8.9-26.1). Median overall survival (OS) from the start of avelumab was not estimable (NE; 95% CI, 20.0-NE). At data cutoff (Jun 2024), 24.2% had ongoing avelumab tx, 30.3% had discontinued without second-line (2L) tx, and 45.5% had received 2L tx (enfortumab vedotin [EV] in 66.7%, pembrolizumab in 20.0%, and PBC in 13.3%). [Conclusions] In this descriptive analysis of real-world data from pts with aUC in Japan, OS with avelumab maintenance tx after 1L ddMVAC was comparable to prior data from the total population. Although pts were not resistant to PBC, 2L EV was more common than 2L PBC.